同时缓释骨形态发生蛋白和氯己定的功能性壳聚糖温敏凝胶的制备

壳聚糖温敏凝胶是一种新型的可注射、在体固化的载体材料,该材料在室温条件下呈生理中性的溶液状态,在37℃左右可由溶液转变成水凝胶。该水凝胶对大分子药物具有良好的缓释效能,但对小分子药物缓释效能极差。 为制备同时缓释生长因子重组人骨形态发生蛋白- 2 (recombined human bone morphogenetic protein - 2, rhBMP-2)和抗菌药物氯己定的功能性壳聚糖温敏凝胶,将小分子药物氯己定先与β-环糊精制备成包结物,再将rhBMP-2与β-环糊精/氯己定包结物共混于壳聚糖温敏凝胶中,通过HAAKE粘度测量仪,对比加入目标药物前后系统的流变学性质,并且分别通过高效液相(high performance liquid chromatography,HPLC)和酶联免疫吸附(enzyme-linked immunosorbent assay, ELISA)方法测量目标药物的体外释放性质,温敏凝胶系统的流变学性质几乎未受加入药物的影响。而氯己定从凝胶系统中释放的速度大大减慢,药物持续释放可保持1月以上。同时,rhBMP-2也获得较好的缓释效果。 通过先行环糊精包结共混的方法,成功制备同时缓释rhBMP-2和氯己定的功能性温敏凝胶。     

壳聚糖基温敏水凝胶的研究进展

壳聚糖是一种由甲壳素脱乙酰化得到的氨基多糖,具有生物相容性、低细胞毒性和可生物降解性等特点。壳聚糖/β-甘油磷酸钠溶液温敏水凝胶在组织工程、药物缓释等领域多有报道,其成胶性能取决于凝胶的组分和浓度。针对单纯壳聚糖水凝胶强度较低、降解较快、药物突释等缺陷,通常对壳聚糖进行改性或引入新材料共混,获得更符合实际需要的壳聚糖基温敏水凝胶。对近年来壳聚糖基水凝胶的研究进展进行综述,包括改性壳聚糖、共混体系等,概述了其在组织工程(软骨、血管、神经修复)、药物缓释(癌症药物缓释、糖尿病治疗)领域中研究和应用的新进展,以期为后续温敏水凝胶的进一步研究提供参考。     

原位可注射壳聚糖基温敏水凝胶的制备及其在预防ESD术后食管狭窄中分阶段释药应用研究

摘要 目的：构建一种可以分阶段释放药物的原位可注射水凝胶，通过直接注射在ESD（Endoscopic Submucosal Dissection，内镜黏膜下剥离术）术后伤口处，形成水凝胶敷料，起到保护伤口的作用。同时凝胶中的两种药物通过分阶段释放的方式，更好地促进伤口的无瘢痕愈合，为ESD术后食管狭窄的预防提供一种新的参考方案。方法：在壳聚糖/β-甘油磷酸钠（CS/β-GP）温敏水凝胶的体系中加入聚多巴胺（PDA），制备壳聚糖/β-甘油磷酸钠/聚多巴胺（CS/?β-GP/PDA）水凝胶。通过在载药水凝胶中加入聚乙二醇-聚乳酸-羟基乙酸（PEG-PLGA）纳米载药微粒制备CS/β-GP/PDA/NPs双载药水凝胶，通过两种载药体系的复合，实现药物的分阶段释放。通过流变学实验测定CS/β-GP、CS/β-GP/PDA、CS/β-GP/PDA/NPs凝胶体系的相转变温度以及凝胶强度。通过高效液相色谱法检测CS/β-GP/PDA/NPs水凝胶中两种药物的释放动力学特征。通过CCK-8细胞增殖实验评价CS/β-GP/PDA、CS/β-GP/PDA/NPs温敏水凝胶的生物相容性。在体外猪食管中，模拟ESD术后创口，通过内镜辅助将水凝胶母液注射在伤口处，并通过内镜观察水凝胶的凝胶状态。结果：得到了粘附性显著增强的壳聚糖/β-甘油磷酸钠/聚多巴胺（CS/β-GP/PDA）凝胶体系。流变学实验证明聚多巴胺（PDA）的加入可以显著降低水凝胶的凝胶温度，缩短原位成胶时间。CCK-8实验显示CS/β-GP/PDA、CS/β-GP/PDA/NPs凝胶体系无潜在的细胞毒性。在体外猪食管模拟实验中，将其凝胶母液注射在伤口处后，可原位形成凝胶，且凝胶贴合伤口，具有较强的粘附性。通过体外释药速率测定，验证了CS/β-GP/PDA/NPs水凝胶中所载两种药物释放速率存在明显差异，可实现药物的分阶段释放。结论：设计的CS/β-GP/PDA/NPs凝胶体系适用于ESD术后的伤口修复，并能够实现分阶段释药，对于预防ESD术后食管狭窄具有潜在的应用价值。     

可注射更昔洛韦温敏型原位凝胶剂的研究

目的：构建温敏型三嵌段共聚物,研究其理化性质以及用其制备的可注射更昔洛韦温敏型原位凝胶剂的制剂特性。方法：以聚乙二醇（PEG）作为亲水嵌段,丙交酯（LA）和β- 丁内酯（β-BL）的无规共聚物PBLA 作为疏水嵌段,采用开环聚合法合成温敏型三嵌段共聚物PBLA-PEG-PBLA,并对其理化性质进行表征,考察其溶液的胶凝温度/ 临界凝胶浓度、流变学性质、通针性和溶蚀行为以及以更昔洛韦作为模型药物、用其制得的可注射载药温敏型原位凝胶剂的体外释放特性。结果：合成的PBLA-PEG-PBLA 嵌段共聚物重均分子质量在6 000 左右,多分散系数为1.5 左右;其溶液临界凝胶浓度（g?mL-1）为5%~10%,质量浓度（g?mL-1）在10%~25% 时胶凝温度为31~35 ℃,接近并略低于体温;其凝胶在低温下储能模量与黏度较小,当温度接近相转变温度后两者迅速增大;其载药凝胶剂累计释放量经拟合显示遵循一级动力学方程,并呈扩散释药机制。结论：较低质量浓度[10%~15%（g?mL-1）] 的PBLA-PEG-PBLA 更符合玻璃体注射要求,更适用于制备可注射载药温敏型原位凝胶剂。     

pH敏感性尼莫地平水凝胶的制备及其性能研究

目的:制备尼莫地平壳聚糖-海藻酸钠水凝胶释药系统.方法:采用复凝聚法制备尼莫地平水凝胶,通过高效液相分析方法考察其对尼莫地平的缓释作用;用转蓝法研究所制水凝胶的释放度,通过改变释放介质的pH值,考察该缓释系统对pH的敏感性.结果:尼莫地平水凝胶在人工胃液中几乎不溶解,累积释放度较低,4h仅释放47%,而人工肠液中具有较高的释放度,可达91%.结论:所制尼莫地平水凝胶具有明显的缓释作用和pH敏感特性.     

聚乙烯醇/葡聚糖复合凝胶的制备及药物释放规律的研究

目的:采用冷冻-解冻物理交联方法制备聚乙烯醇(PVA)和葡聚糖(Dextran)混合凝胶.并考察复合凝胶药物释放规律.方法:含有胰岛素的PVA/Dextran溶液置于-20℃条件下冷冻8 h,在室温下解冻4 h,反复冷冻-解冻数次制备得到胰岛素PVA/Dextran复合凝胶,反相高效液相色谱法考察了胰岛素的体外释放行为.结果:胰岛素复合凝胶体外释放模式符合Higuchi扩散方程.当PVA/Dextran比例从100/0降到80/20,胰岛素释放速率明显增加,最大释放率从45%增加到65%.当冷冻-解冻循环次数从2增加到6,胰岛素达到最大释放的时间从24 h增加到45 h,最大释放率从70%降到50%.释放介质的温度的升高能显著增加胰岛素的释放速率.结论:PVA/Dextran制备的胰岛素复合凝胶具有良好的缓释效果.PVA/Dextran复合凝胶是一种较有前景的水凝胶药物载体.     

壳聚糖及其衍生物温敏水凝胶研究进展及其应用

壳聚糖基温度敏感性水凝胶具有原位成胶的特点,广泛应用于组织工程修复和药物释放载体的研究中。近年来围绕壳聚糖及其衍生物温敏水凝胶的研究逐年增多,本文综述了近年来壳聚糖基温敏水凝胶的研究进展及其应用。     

壳聚糖温敏性凝胶的制备及其热敏性实验研究

目的：用壳聚糖作为一种生物材料,和甘油磷酸盐（GPS）反应制备温敏性凝胶,使其在植入体内后发生形态上的变化。从而是达到用于组织缺损和药物释放的目的。方法：将不同浓度的壳聚糖和GPS反应生成凝胶,测定其pH值和在不同温度下的凝固时间。结果：凝胶的pH值随壳聚糖和GPS的浓度的增加而增加。同时也随溶解壳聚糖的酸浓度增加下降,其凝固时间随pH值和随温度的增加而减少。结论：壳聚糖与GPS反应,能制备出在低温下呈流体状液体,而当温度升高到体温时则成凝固的温敏性凝胶。     

酮戊二酸改性壳聚糖微球的制备及其对来氟米特的缓释

采用反相悬浮法制备交联壳聚糖微球,再与α-酮戊二酸反应生成Schiff碱,以NaBH_4还原制得改性壳聚糖微球.用FT-IR,SEM和XRD进行表征.并以来氟米特(LEF)为模型药物,考察了其缓释效果.结果显示:微球对药物的最大包封率为94%,载药量为62%,在缓释初期2 h内微球平均释放药量的16%,后期则呈现缓慢释放的趋势.本论文采用的微粒的药物承载量和释放速度既保证了药物的药效又降低了药物释放速率过快引起的对人体的不良反应.     

5-FU壳聚糖-阿拉伯胶缓释微囊的制备工艺研究

研究以壳聚糖和阿拉伯胶为基质材料,制备5-FU缓释微囊.以微囊的药物包封率为制备工艺优化指标,利用复凝聚法,通过L_9(3~4)正交实验得出微囊的最佳制备工艺条件.以最佳制备工艺条件制备的5-FU缓释微囊,所制微囊形态及稳定性较好.体外释放研究表明,微囊有良好的缓释效果.     

Chitosan film as rhBMP2 carrier: delivery properties for bone tissue application

Tissue engineering approaches need biomaterials with suitable properties to provide an appropriate environment for cell attachment and growth. The performance of these biomaterials can be greatly enhanced through the incorporation of bioactive agents. For this reason, we developed chitosan films with cell-attachment ability, rhBMP-2 carrier capacity, and good in vivo performance, and we employ them as covering for implantable materials. In this work, we have tried to explain how the rh-BMP2 is delivered to the surroundings from the development chitosan films. Protein diffusion from film, film stability versus in vitro dissolution, and biodegradation were evaluated to study rhBMP-2 delivery. Our results show that chitosan film has sufficiently good features to be used as an rhBMP-2 carrier. A low diffusion rate was observed, which was sufficient to quickly induce an in vitro differentiation stimulus, although heavily activated films retain more than 80-85% of the protein on the film. On the other hand, we estimated that chitosan film dissolution due to initial acidification in the wound environment is no more than 15-20%. We also estimated chitosan film response to lysozyme and concluded that degradation via this process proceeded at a slow kinetic rate. In addition, rhBMP-2 in vitro activity after film processing, as well as in vivo film behavior, were studied. We confirm that rhBMP-2 remains active on the film and after release, both in vitro and in vivo. These results support the conclusion that the developed chitosan film allows sustained release of the rhBMP-2 osteoinductive protein and could be used as an activated coat for implant and surgical prosthesis.     

Regulation of the binding of the BMP-2 growth factor with collagen by blood plasma fibronectin

The release kinetics of recombinant human bone morphogenic factor 2 (rhBMP-2) from collagen hydrogel in the presence of human blood plasma have been studied. The expulsion of rhBMP-2 from the collagen-BMP-2 complex by the competitive adhesion of collagen-binding proteins penetrating from plasma was firstly recognized. It was experimentally proven that that blood plasma fibronectin is the main collagen-binding protein, which is responsible for the controlled release of rhBMP-2. As a result, a new collagen hydrogel with the incorporation of fibronectin was created which retained rhBMP-2 for a twice longer period as compared to the ordinary collagen hydrogel. A distinctive feature of this new collagen-fibronectin matrix is the slow release of rhBMP-2 in the first three days which allows for the avoiding of adverse effects in clinics caused by the rapid release of large amounts of rhBMP-2 from collagen hydrogel.     

Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:beta-cyclodextrin complex

The purpose of this study was to achieve a better therapeutic efficacy and patient compliance in the treatment for vaginitis. Clotrimazole (1%) has been formulated in a vaginal gel using the thermosensitive polymer Pluronic F127 (20%) together with mucoadhesive polymers such as Carbopol 934 and hydroxypropylmethylcellulose (0.2% for both). To increase its aqueous solubility, clotrimazole was incorporated as its inclusion complex with 1:1 molar ratio with beta-cyclodextrin. The inclusion complex was thoroughly characterized using various techniques, including 1H NMR spectroscopy, FT IR spectrophotometry, differential scanning calorimetry, scanning electron microscopy, phase solubility studies, and determination of stability constant (k(1:1)). The gelation temperature and rheological behavior of different formulations at varying temperatures were measured. In vitro release profiles of the gels were determined in pH 5.5 citrate buffer. It was observed that complexation with cyclodextrin slowed down the release of clotrimazole considerably. Carbopol 934, on the other hand, was found to interact with beta-cyclodextrin, inducing precipitation. As far as rheological properties are concerned, thermosensitive in situ gelling was obtained with formulations containing drug:cyclodextrin complex rather than with free drug. Thus, the optimum formulation for a controlled-release thermosensitive and mucoadhesive vaginal gel was determined to be clotrimazole:beta-cyclodextrin 1% with 0.2% hydroxypropylmethylcellulose in Pluronic F127 gel (20%) providing continuous and prolonged release of active material above MIC values.     

Design and development of hydrogel beads for targeted drug delivery to the colon

The purpose of this research was to develop and evaluate a multiparticulate system of chitosan hydrogel beads exploiting pH-sensitive property and specific biodegradability for colon-targeted delivery of satranidazole. Chitosan hydrogel beads were prepared by the cross-linking method followed by enteric coating with Eudragit S100. All formulations were evaluated for particle size, encapsulation efficiency, swellability, and in vitro drug release. The size of the beads was found to range from 1.04±0.82 mm to 1.95±0.05 mm. The amount of the drug released after 24 hours from the formulation was found to be 97.67%±1.25% in the presence of extracellular enzymes as compared with 64.71%±1.91% and 96.52%±1.81% release of drug after 3 and 6 days of enzyme induction, respectively, in the presence of 4% cecal content. Degradation of the chitosan hydrogel beads in the presence of extracellular enzymes as compared with rat cecal and colonic enzymes indicates the potential of this multiparticulate system to serve as a carrier to deliver macromolecules specifically to the colon and can be offered as a substitute in vitro system for performing degradation studies. Studies demonstrated that orally administered chitosan hydrogel beads can be used effectively for the delivery of drug to the colon. Published: July 13, 2007     

Cytotoxicity and biocompatibility evaluation of N,O-carboxymethyl chitosan/oxidized alginate hydrogel for drug delivery application

In this paper, covalently cross-linked hydrogel composed of N,O-carboxymethyl chitosan and oxidized alginate was developed intending for drug delivery application. In vitro/vivo cytocompatibility and biocompatibility of the developed hydrogel were preliminary evaluated. In vitro cytocompatibility test showed that the developed hydrogel exhibited good cytocompatibility against NH3T3 cells after 3-day incubation. According to the results of acute toxicity test, there was no obvious cytotoxicity for major organs during the period of 21-day intraperitoneal administration. Meanwhile, the developed hydrogel did not induce any cutaneous reaction within 72 h of subcutaneous injection followed by slow degradation and adsorption with the time evolution. Moreover, the extraction of developed hydrogel had nearly 0% of hemolysis ratio, which indicated the good hemocompatibility of hydrogel. Based on the above results, it may be concluded that the developed N,O-carboxymethyl chitosan/oxidized alginate hydrogel with non-cytotoxicity and good biocompatibility might suitable for the various drug delivery applications.     

Thermosensitive and Mucoadhesive Sol-Gel Composites of Paclitaxel/Dimethyl-β-Cyclodextrin for Buccal Delivery

The purpose of this study was to develop a buccal paclitaxel delivery system using the thermosensitive polymer Pluronic F127 (PF127) and the mucoadhesive polymer polyethylene oxide (PEO). The anticancer agent paclitaxel is usually used to treat ovarian, breast, and non-small-cell lung cancer. To improve its aqueous solubility, paclitaxel was incorporated into an inclusion complex with (2,6-di-O-methyl)-β-cyclodextrin (DMβCD). The formation of the paclitaxel inclusion complex was evaluated using various techniques, including x-ray diffractometry (XRD), Fourier-transform infrared (FT-IR) spectrophotometry, differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Hydrogels were prepared using a cold method. Concentrations of 18, 20, and 23% (w/v) PF127 were dissolved in distilled water including paclitaxel and stored overnight in a refrigerator at 4°C. PEO was added at concentrations of 0.1, 0.2, 0.4, 0.8, and 1% (w/v). Each formulation included paclitaxel (0.5 mg/mL). The sol-gel transition temperature of the hydrogels was measured using the tube-inverting method. Drug release from the hydrogels was measured using a Franz diffusion cell containing pH 7.4 phosphate-buffered solution (PBS) buffer at 37°C. The cytotoxicity of each formulation was measured using the MTT assay with a human oral cancer cell (KB cell). The sol-gel transition temperature of the hydrogel decreased when PF127 was present and varied according to the presence of mucoadhesive polymers. The in vitro release was sustained and the release rate was slowed by the addition of the mucoadhesive polymer. The cytotoxicity of the blank formulation was low, although the drug-loaded hydrogel showed acceptable cytotoxicity. The results of our study suggest that the combination of a PF 127-based mucoadhesive hydrogel formulation and inclusion complexes improves the in vitro release and cytotoxic effect of paclitaxel.     

In vitro and in vivo investigation of a novel two-phase delivery system of 2-methoxyestradiol liposomes hydrogel

For improving effectiveness of conventional chemotherapy of subcutaneous tumor, we selected 2-methoxyestradiol (2-ME) as a model drug, local injectable PLGA-PEG-PLGA copolymer thermosensitive hydrogel loading 2-ME liposomes instead of free 2-ME as a novel two-phase drug delivery system was developed, which avoid rapid clearance of liposomes follwing systemic administration. This new transport system was characterized in vitro and in vivo including rheological behavior, thermo-sensitiveness, stability, released character and intratumoral delivery. The PLGA-PEG-PLGA copolymer solution exhibited still reversible thermosensitive property and better syringeability after incorporated 2-ME liposomes. The 2-ME liposomes were demonstrated stable in the hydrogel by five methods such as scanning electron microscopy (SEM), fluorescent labeling, opalescence, particle size and ultrafiltration methods. Results showed that intact liposomes could be released from the hydrogel and following zero-order model, and sustained release one–two months in vitro and in vivo. In vivo release data demonstrating that 2-ME liposomes could be transported to tumor site, improved therapeutic efficacy and bioavailability of 2-ME liposomes in subcutaneous tumor chemotherapy.     

壳聚糖装载猪胸腺肽微球给药

目的：以猪胸腺肽为芯材、壳聚糖为壁材,采用乳化交联结合单凝聚法制备猪胸腺肽壳聚糖口服微球。方法：以壁材浓度、交联剂含量、油水比值、芯材壁材比值为四因素设计正交实验,确定微球最佳制备条件,并对其体外释放及稳定性进行研究。结果：制备微球最优化条件为壳聚糖浓度1％、25％戊二醛含量7％、油水比值2：1、壳聚糖与胸腺肽比值1：1;微球在pH1．5的HC1溶液中2h释放30％,在pH6．8及7．4的PBS缓冲液中最终释放度约80％,并在24h达到释放终点;微球30rain突释率约为10％,1h释放率约为20％,其后缓慢而持续地释放;猪胸腺肽壳聚糖微球在0℃保存8个月时微球外观及形态没有差异,药物剩余率约为91．8％。结论：采用乳化交联结合单凝聚法制备的猪胸腺肽壳聚糖口服微球为缓释给药系统的临床应用奠定了理论基础,具有重要的实际应用价值和社会意义。     

Rheological characterisation of a novel thermosensitive chitosan/poly(vinyl alcohol) blend hydrogel

Thermosensitive hydrogels that are triggered by changes in environmental temperature thus resulting in in situ hydrogel formation have recently attracted the attention of many investigators for biomedical applications. In the current work, the thermosensitive hydrogel was prepared through the mixture of chitosan (CS), poly(vinyl alcohol) (PVA) and sodium bicarbonate. The mixture was liquid aqueous solutions at low temperature (about 4 °C), but a gel under physiological conditions. The hydrogel was characterized by FTIR, swelling and rheological analysis. The effect of hydrogel composition and temperature on both the gel process and the gel strength was investigated from which possible hydrogel formation mechanisms were inferred. In addition, the hydrogel interior morphology as well as porosity of structure was evaluated by scanning electron microscopy (SEM). The potential of the hydrogels as vehicles for delivering bovine serum albumin (BSA) were also examined. In this study, the physically crosslinked chitosan/PVA gel was prepared under mild conditions without organic solvent, high temperature or harsh pH. The viscoelastic properties, as investigated rheologically, indicate that the gel had good mechanical strength. The gel formed implants in situ in response to temperature change, from low temperature (about 4 °C) to body temperature, which was very suitable for local and sustained delivery of proteins, cell encapsulation and tissue engineering.